leisure time -WSS

leisure time

author：comprehensive 2025-08-27 22:29:35 - browse：37663

Two researchers look at a projection screen displaying medical devices, scientific graphs and DNA — health tech coverage from STAT — Adobe

The federal government’s plan to boost its oversight of the use of artificial intelligence tools in health care drew censure from startups arguing that overregulation stifles new ideas. But as Washington forges ahead, founders say they’re in the dark about who will be regulated and how — and they’re urging policymakers to offer clarity.

As they race for a slice of the $4 trillion U.S. health care market, AI founders and investors say regulatory uncertainty is a hurdle, forcing them to build more slowly and meticulously document for fear of potential audits. That makes it harder to keep up with the tech industry’s breakneck pace, they tell STAT.

The regulatory uncertainty adds to the many challenges dogging young health tech ventures today: Last year investments in digital health startups shriveled to their lowest annual total since 2019, and leaders are desperate to preserve what little funds they have, including through layoffs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： ACIP vaccine advisory panel sees its vacancies filled

entertainment

WSS

Is there really a nursing shortage in the U.S.?

CZI to create biohub to build anti

STAT Readout: Friday, Oct. 20 biotech updates

Readout LOUD podcast: Live from the 2023 STAT Summit

Juul documents reveal insider tactics on political lobbying

Roche drug slashes death risk in early

explore

leisure time

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Resistance to opioid

Affirmative action in medical school literally saved lives

Why Eli Lilly’s earnings didn’t quite live up to the hype

Walensky prepares to leave CDC — and Congress — behind

Roivant's CEO is a star, but biotech's black hole persists

The high cost of giving birth even with insurance

J&J lung cancer data amount to new salvo against AstraZeneca

Cancer drug shortages should be causing more outrage

Roivant's CEO is a star, but biotech's black hole persists

hotspot

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Latigo launches with $135 million for Vertex

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Having children helps parents live longer, especially after age 80

Report cites 'urgent' need to recruit more diverse clinical trial participants

ACIP vaccine advisory panel sees its vacancies filled

entertainment

focus

knowledge

hotspot